PE20161344A1 - Determinantes de respuesta del cancer a la inmunoterapia - Google Patents
Determinantes de respuesta del cancer a la inmunoterapiaInfo
- Publication number
- PE20161344A1 PE20161344A1 PE2016000989A PE2016000989A PE20161344A1 PE 20161344 A1 PE20161344 A1 PE 20161344A1 PE 2016000989 A PE2016000989 A PE 2016000989A PE 2016000989 A PE2016000989 A PE 2016000989A PE 20161344 A1 PE20161344 A1 PE 20161344A1
- Authority
- PE
- Peru
- Prior art keywords
- antigen
- composition
- determinants
- immunotherapy
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Se refiere a una composicion que comprende multiples neoepitopos caracterizados porque: a) comprenden una mutacion somatica; b) se unen al complejo mayor de histocompatibilidad de clase I del sujeto con un IC50 inferior o igual a 500 nM.; c) comprenden un tetrapeptido que es una region conservada entre los antigenos reconocido por un receptor de celulas T tal como AARA, ALLN, entre otros y d) comparten una secuencia de consenso con un antigeno de un agente infeccioso. Ademas comprende un inhibidor de puntos de control del sistema inmunitario tal como un anticuerpo o fragmento de union al antigeno de este que se une a un regulador de respuesta inmunitaria seleccionado de CTLA4, PD1, PD-L1 y OX40; tambien se refiera a un kit de deteccion. Dicha composicion es util en el tratamiento de cancer
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461923183P | 2014-01-02 | 2014-01-02 | |
US201462066034P | 2014-10-20 | 2014-10-20 | |
US201462072893P | 2014-10-30 | 2014-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20161344A1 true PE20161344A1 (es) | 2016-12-23 |
Family
ID=53494217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016000989A PE20161344A1 (es) | 2014-01-02 | 2014-12-23 | Determinantes de respuesta del cancer a la inmunoterapia |
Country Status (15)
Country | Link |
---|---|
US (1) | US20160326597A1 (es) |
EP (1) | EP3090066A4 (es) |
JP (1) | JP2017504324A (es) |
KR (1) | KR20160102314A (es) |
CN (1) | CN106164289A (es) |
AU (1) | AU2014374020A1 (es) |
BR (1) | BR112016015399A2 (es) |
CA (1) | CA2935214A1 (es) |
CL (1) | CL2016001708A1 (es) |
MX (1) | MX2016008771A (es) |
PE (1) | PE20161344A1 (es) |
PH (1) | PH12016501329A1 (es) |
RU (1) | RU2707530C2 (es) |
SG (2) | SG10201805674YA (es) |
WO (1) | WO2015103037A2 (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
KR20210069124A (ko) | 2014-11-13 | 2021-06-10 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
MA40737A (fr) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
WO2016146143A1 (en) * | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
CA3172682A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
JP6925980B2 (ja) | 2015-05-13 | 2021-08-25 | アジェナス インコーポレイテッド | がんの処置および予防のためのワクチン |
GB201516047D0 (en) * | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
US11623001B2 (en) | 2015-10-12 | 2023-04-11 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
AU2016338947B2 (en) * | 2015-10-12 | 2020-06-04 | Nantomics, Llc | Viral neoepitopes and uses thereof |
CN108701173A (zh) * | 2015-10-12 | 2018-10-23 | 南托米克斯有限责任公司 | 用于发现预测对检查点抑制剂敏感的msi和新表位的***、组合物和方法 |
EP3719143B1 (en) | 2015-10-23 | 2023-07-26 | Novartis AG | Method of deriving a value for percent biomarker positivity for selected cells present in a field of view |
TWI733719B (zh) | 2015-12-07 | 2021-07-21 | 美商河谷控股Ip有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
CN108601731A (zh) | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
EP3400005A1 (en) * | 2016-01-08 | 2018-11-14 | Vaccibody AS | Neoepitope rna cancer vaccine |
KR20180107257A (ko) | 2016-02-19 | 2018-10-01 | 난트 홀딩스 아이피, 엘엘씨 | 면역원 조절 방법 (methods of immunogenic modulation) |
CN109196121B (zh) | 2016-02-29 | 2022-01-04 | 基因泰克公司 | 用于癌症的治疗和诊断方法 |
CN109476731A (zh) | 2016-02-29 | 2019-03-15 | 基础医药有限公司 | 治疗癌症的方法 |
US20190080044A1 (en) * | 2016-03-15 | 2019-03-14 | Repertoire Genesis Incorporation | Monitoring and diagnosis for immunotherapy, and design for therapeutic agent |
FI3429618T3 (fi) * | 2016-03-16 | 2024-03-15 | Amal Therapeutics Sa | Immuunijäjestelmän tarkistuspisteen modulaattorin ja soluun tunkeutuvan peptidin, cargon ja tlr-peptidiagonistin kompleksin yhdistelmä lääketieteelliseen käyttöön |
EP3468600A4 (en) * | 2016-06-10 | 2019-11-13 | IO Therapeutics, Inc. | RETINOID COMPOUNDS AND RELECTIVE REXINOIDS OF THE RECEPTOR AND IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER |
WO2018005276A1 (en) * | 2016-06-29 | 2018-01-04 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
AU2017331949A1 (en) | 2016-09-21 | 2019-01-31 | Amal Therapeutics Sa | Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer |
EP3516081A4 (en) * | 2016-09-23 | 2020-07-29 | Memorial Sloan Kettering Cancer Center | DETERMINANTS OF CANCER REACTION TO IMMUNOTHERAPY |
AU2017339517B2 (en) * | 2016-10-06 | 2024-03-14 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
WO2018102613A2 (en) | 2016-12-01 | 2018-06-07 | Nantomics, Llc | Tumor antigenicity processing and presentation |
WO2018112449A2 (en) | 2016-12-16 | 2018-06-21 | Nant Holdings Ip, Llc | Live cell imaging systems and methods to validate triggering of immune response |
US20190369096A1 (en) * | 2017-01-13 | 2019-12-05 | Nantbio, Inc. | Validation of neoepitope-based treatment |
US20200232040A1 (en) | 2017-01-18 | 2020-07-23 | Vinod P. Balachandran | Neoantigens and uses thereof for treating cancer |
WO2018146128A1 (en) * | 2017-02-07 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy |
US20200102618A1 (en) * | 2017-03-17 | 2020-04-02 | Nantomics, Llc | LIQUID BIOPSY FOR cfRNA |
MA50056A (fr) * | 2017-03-31 | 2020-02-05 | Bristol Myers Squibb Co | Procédés de traitement de tumeur |
JP2020522479A (ja) | 2017-06-02 | 2020-07-30 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | 個別化された癌ワクチンを作製する方法 |
GB201710815D0 (en) * | 2017-07-05 | 2017-08-16 | Francis Crick Inst Ltd | Method |
CN111432837A (zh) * | 2017-09-25 | 2020-07-17 | 纪念斯隆凯特琳癌症中心 | 肿瘤突变负荷和检查点免疫疗法 |
KR20200087143A (ko) | 2017-10-10 | 2020-07-20 | 그릿스톤 온콜로지, 인코포레이티드 | 핫스팟을 이용한 신생항원 동정 |
CN111247169A (zh) | 2017-10-15 | 2020-06-05 | 百时美施贵宝公司 | ***的方法 |
CN111566225A (zh) | 2017-11-03 | 2020-08-21 | 夸登特健康公司 | 归一化肿瘤突变负荷 |
CN111566484A (zh) * | 2017-11-09 | 2020-08-21 | 宾夕法尼亚大学董事会 | 细胞外囊泡蛋白及其在癌症诊断、预测对疗法的反应和治疗中的用途 |
CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
KR20200093438A (ko) * | 2017-12-01 | 2020-08-05 | 일루미나, 인코포레이티드 | 체성 돌연변이 클론형성능을 결정하기 위한 방법 및 시스템 |
CN108009400B (zh) * | 2018-01-11 | 2018-07-06 | 至本医疗科技(上海)有限公司 | 全基因组肿瘤突变负荷预测方法、设备以及存储介质 |
US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
MA52363A (fr) | 2018-04-26 | 2021-03-03 | Agenus Inc | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
SG11202100344WA (en) | 2018-07-23 | 2021-02-25 | Guardant Health Inc | Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage |
SG11202101400UA (en) | 2018-08-31 | 2021-03-30 | Guardant Health Inc | Microsatellite instability detection in cell-free dna |
CN109371005B (zh) * | 2018-11-12 | 2022-09-30 | 上海市东方医院(同济大学附属东方医院) | 一种hla-0201限制性padi4表位多肽及其应用 |
JP2022514218A (ja) * | 2018-12-12 | 2022-02-10 | メディミューン,エルエルシー | 血液に基づく腫瘍遺伝子変異量が、非小細胞肺がんの全生存期間の予測に役立つ |
WO2020206127A1 (en) * | 2019-04-05 | 2020-10-08 | Illumina, Inc. | Quantitative score of hla diversity |
NL2024107B1 (en) * | 2019-10-26 | 2021-07-19 | Vitroscan B V | Compositions for Patient Specific Immunotherapy |
CN111088349B (zh) * | 2020-02-14 | 2023-04-28 | 深圳市宝安区妇幼保健院 | Kir3dl1基因分型引物组及其应用 |
GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
WO2022217136A1 (en) * | 2021-04-10 | 2022-10-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | A multiomic approach to modeling of gene regulatory networks in multiple myeloma |
AU2021461416A1 (en) | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9826143D0 (en) * | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
US9222938B2 (en) * | 2001-12-04 | 2015-12-29 | Michael Tainsky | Neoepitope detection of disease using protein arrays |
WO2006050172A2 (en) * | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
ES2564841T3 (es) * | 2010-05-14 | 2016-03-29 | The General Hospital Corporation | Composiciones y métodos para identificar neoantígenos específicos de un tumor |
GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
-
2014
- 2014-12-23 AU AU2014374020A patent/AU2014374020A1/en not_active Abandoned
- 2014-12-23 US US15/109,464 patent/US20160326597A1/en not_active Abandoned
- 2014-12-23 CA CA2935214A patent/CA2935214A1/en not_active Abandoned
- 2014-12-23 EP EP14876694.2A patent/EP3090066A4/en not_active Withdrawn
- 2014-12-23 WO PCT/US2014/072125 patent/WO2015103037A2/en active Application Filing
- 2014-12-23 SG SG10201805674YA patent/SG10201805674YA/en unknown
- 2014-12-23 SG SG11201605432RA patent/SG11201605432RA/en unknown
- 2014-12-23 JP JP2016544613A patent/JP2017504324A/ja active Pending
- 2014-12-23 CN CN201480075287.2A patent/CN106164289A/zh active Pending
- 2014-12-23 BR BR112016015399A patent/BR112016015399A2/pt not_active IP Right Cessation
- 2014-12-23 RU RU2016131207A patent/RU2707530C2/ru not_active IP Right Cessation
- 2014-12-23 MX MX2016008771A patent/MX2016008771A/es unknown
- 2014-12-23 KR KR1020167021093A patent/KR20160102314A/ko not_active Application Discontinuation
- 2014-12-23 PE PE2016000989A patent/PE20161344A1/es unknown
-
2016
- 2016-07-01 CL CL2016001708A patent/CL2016001708A1/es unknown
- 2016-07-04 PH PH12016501329A patent/PH12016501329A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017504324A (ja) | 2017-02-09 |
PH12016501329A1 (en) | 2016-10-03 |
EP3090066A4 (en) | 2017-08-30 |
WO2015103037A3 (en) | 2015-11-05 |
BR112016015399A2 (pt) | 2017-10-24 |
SG10201805674YA (en) | 2018-08-30 |
EP3090066A2 (en) | 2016-11-09 |
KR20160102314A (ko) | 2016-08-29 |
RU2016131207A3 (es) | 2018-06-22 |
MX2016008771A (es) | 2016-12-20 |
US20160326597A1 (en) | 2016-11-10 |
WO2015103037A2 (en) | 2015-07-09 |
SG11201605432RA (en) | 2016-07-28 |
CN106164289A (zh) | 2016-11-23 |
AU2014374020A1 (en) | 2016-08-18 |
CL2016001708A1 (es) | 2017-03-17 |
RU2707530C2 (ru) | 2019-11-27 |
RU2016131207A (ru) | 2018-02-07 |
CA2935214A1 (en) | 2015-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20161344A1 (es) | Determinantes de respuesta del cancer a la inmunoterapia | |
CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
CY1124190T1 (el) | Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση | |
CO2019000946A2 (es) | Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos | |
CL2017001610A1 (es) | Anticuerpos humanos para hemagglutinina de influenza | |
CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
PE20170125A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
CO2017007619A2 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
PE20170289A1 (es) | Anticuerpos anti tigit | |
TR201901445T4 (tr) | Il2rbeta/yaygın gamma zinciri antikorları. | |
SV2018005678A (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
SG10201901057UA (en) | Anti-pd-l1 antibodies | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
BR112016022727A8 (pt) | imunorreceptores específicos de claudina-6 e epítopos de células t | |
PE20161392A1 (es) | Combinacion de lenalidomida y constructo de polipeptido, y sus usos | |
PH12016501976A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
MA40682A (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
PE20160690A1 (es) | Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos | |
PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
AR085591A1 (es) | Anticuerpos del antigeno carcinoembrionario humano (cea) | |
EA201791270A1 (ru) | Модифицированные april-связывающие антитела |